Once upon a time in oncology – will we definitely win a war against cancer? Critical review of the progresses in cancer therapies

Q4 Medicine Nowotwory Pub Date : 2023-10-27 DOI:10.5603/njo.96917
Bogusław Maciejewski, Daniel Bula, Justyna Rembak-Szynkiewicz
{"title":"Once upon a time in oncology – will we definitely win a war against cancer? Critical review of the progresses in cancer therapies","authors":"Bogusław Maciejewski, Daniel Bula, Justyna Rembak-Szynkiewicz","doi":"10.5603/njo.96917","DOIUrl":null,"url":null,"abstract":"Aim of the present review of various classic and novel therapeutic strategies in oncology is critical discussion of its efficacy to answer whether once upon a time is it real and possible to win a war against cancer. Although technological progress in radiotherapy (RT) has led to develop many sophisticated 3D, 4D techniques, the use of the RT as a sole modality has become more and more limited to the tumours in early stage of disease, in favour of combined surgery-RT-chemotherapy (CHT) therapies. Nevertheless patients curability has never reached the level higher than 95% (stereotactic hypofractionated RT – limited too small tumours only). The CHT for solid malignant tumours is not effective enough, and therefore it is mainly combined with Surg and RT as a method of the boost. Common use of partial or complete regression (PR, CR) as end-points of its efficacy is irrelevant, since it is quasi-quantified tumour cell clearance but not cell kill effects, and the regrowth delay (time of tumour regrowth to the size, volume at the beginning of therapy) is the only proper end-point. Efficacy of various genetic, molecular, immuno, and antiangiogenic modalities tested in many clinical studies is critically discussed, and it has generally showed some therapeutic benefits, but not very spectacular. It has been well documented that genotypes and phenotypes of the tumours (even within the same location, stage and histology) are individually highly heterogeneous. Therefore, the term “average probability” referred to individual patients becomes meaningless, and moreover, this term has never been replaced by “certainty” yet. Statistics of many studies and trials consist of various pitfalls and biases. Thus, although we and our patients are more often winners on the individual battlefields, the winning once upon a time of whole war against cancer seems to be possible (hope), but not for sure (real).","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"67 4","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nowotwory","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/njo.96917","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Aim of the present review of various classic and novel therapeutic strategies in oncology is critical discussion of its efficacy to answer whether once upon a time is it real and possible to win a war against cancer. Although technological progress in radiotherapy (RT) has led to develop many sophisticated 3D, 4D techniques, the use of the RT as a sole modality has become more and more limited to the tumours in early stage of disease, in favour of combined surgery-RT-chemotherapy (CHT) therapies. Nevertheless patients curability has never reached the level higher than 95% (stereotactic hypofractionated RT – limited too small tumours only). The CHT for solid malignant tumours is not effective enough, and therefore it is mainly combined with Surg and RT as a method of the boost. Common use of partial or complete regression (PR, CR) as end-points of its efficacy is irrelevant, since it is quasi-quantified tumour cell clearance but not cell kill effects, and the regrowth delay (time of tumour regrowth to the size, volume at the beginning of therapy) is the only proper end-point. Efficacy of various genetic, molecular, immuno, and antiangiogenic modalities tested in many clinical studies is critically discussed, and it has generally showed some therapeutic benefits, but not very spectacular. It has been well documented that genotypes and phenotypes of the tumours (even within the same location, stage and histology) are individually highly heterogeneous. Therefore, the term “average probability” referred to individual patients becomes meaningless, and moreover, this term has never been replaced by “certainty” yet. Statistics of many studies and trials consist of various pitfalls and biases. Thus, although we and our patients are more often winners on the individual battlefields, the winning once upon a time of whole war against cancer seems to be possible (hope), but not for sure (real).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
曾几何时,在肿瘤学领域,我们一定会赢得对抗癌症的战争吗?癌症治疗进展综述
本文回顾了肿瘤学中各种经典和新颖的治疗策略,目的是对其疗效进行批判性的讨论,以回答从前是否真的和可能赢得与癌症的战争。尽管放射治疗(RT)的技术进步导致了许多复杂的3D、4D技术的发展,但将RT作为唯一方式的使用越来越局限于疾病早期的肿瘤,而倾向于手术-RT-化疗(CHT)联合治疗。然而,患者的治愈率从未达到95%以上的水平(立体定向低分割放疗限制过小的肿瘤)。对于实体恶性肿瘤,CHT的疗效不够,因此主要与外科手术和RT相结合作为一种增强方法。通常使用部分或完全回归(PR, CR)作为其疗效的终点是不相关的,因为它是准量化的肿瘤细胞清除率,而不是细胞杀伤效果,再生延迟(肿瘤再生到治疗开始时的大小,体积的时间)是唯一合适的终点。在许多临床研究中测试的各种遗传、分子、免疫和抗血管生成模式的功效被批判性地讨论,并且通常显示出一些治疗益处,但不是非常引人注目。有充分的证据表明,肿瘤的基因型和表型(即使在相同的位置,阶段和组织学)是高度异质性的。因此,单个患者的“平均概率”一词就变得没有意义了,而且,这个词还没有被“确定性”所取代。许多研究和试验的统计数据包含各种陷阱和偏差。因此,尽管我们和我们的病人在个别战场上更多地是胜利者,但从前战胜癌症的整体战争似乎是可能的(希望),但不确定(现实)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nowotwory
Nowotwory Medicine-Oncology
CiteScore
0.90
自引率
0.00%
发文量
44
期刊介绍: NOWOTWORY Journal of Oncology publishes papers which cover all aspects of oncology but concentrates on clinical studies, both research orientated and treatment orientated, rather than on laboratory studies. Contributions are also welcomed from the fields of epidemiology, tumor pathology, radiobiology and radiation physics.
期刊最新文献
Once upon a time in oncology – will we definitely win a war against cancer? Critical review of the progresses in cancer therapies Wnt pathways in focus – mapping current clinical trials across cancer spectrum The influence of fluid therapy on short and long – term outcome in patients undergoing liver resection for malignant indications Pharmacological prevention methods in patients with cardiovascular disease with breast cancer – when, how, and for whom? Retrospective analysis of the treatment of BRCA1 and BRCA2 mutation carriers – the experience of a single-center tertiary institution
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1